The cannabis withdrawal syndrome: current insights.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical literature without systematic review methodology.
PubMed 28490916 · doi:10.2147/SAR.S109576
What was done
Narrative review synthesizing animal and human literature on the neurobiology, clinical presentation, severity factors, and pharmacological treatments for cannabis withdrawal syndrome.
What was found
The abstract reports no numerical outcome statistics. It reports that CB1 receptor desensitization and downregulation begins reversing within 2 days of abstinence and normalizes within 4 weeks. Women report stronger withdrawal including physical symptoms such as nausea and stomach pain. Promising therapeutic results were noted for gabapentin and delta-9-tetrahydrocannabinol analogues, and mirtazapine showed benefit for withdrawal insomnia. Small studies indicated venlafaxine may worsen symptoms, while other antidepressants, atomoxetine, lithium, buspirone, and divalproex had no relevant effect.
Why it matters
It outlines the biological timeline of CB1 receptor recovery during abstinence and clarifies which off-label medications show potential benefit versus those that appear ineffective or counterproductive.
Limits
The paper is a narrative review without systematic search criteria or meta-analytic data. No exact sample sizes, effect sizes, or quantitative confidence intervals are provided in the abstract. Much of the underlying pharmacotherapy data relies on small studies.
Cited by
- supports Cessation of cannabis use causes withdrawal characterized primarily by psychological symptoms including anxiety, irritability, depression, insomnia, and craving.